Cargando…

Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19

Detalles Bibliográficos
Autores principales:	Piñana, José Luis, Garcia-Sanz, Ramon, Martino, Rodrigo, Garcia-Roa, María, Martin-Martin, Gabriel Andrés, Risco-Gálvez, Irene, Tormo, Mar, Martinez-Barranco, Pilar, Marcos-Corrales, Sara, Calabuig, Marisa, Conesa, Venancio, Teruel, Anabel, Ruiz-Pérez, Sara, Solano, Carlos, Navarro, David, Cedillo, Ángel, Sureda,, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674106/ https://www.ncbi.nlm.nih.gov/pubmed/34905620 http://dx.doi.org/10.1182/bloodadvances.2021006326

Ejemplares similares

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
por: Piñana, José Luis, et al.
Publicado: (2022)

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
por: Piñana, José Luis, et al.
Publicado: (2023)

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
por: Piñana, José Luis, et al.
Publicado: (2023)

Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients
por: Torres, Ignacio, et al.
Publicado: (2022)

Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study
por: Piñana, José Luis, et al.
Publicado: (2018)

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
por: Piñana, José Luis, et al.
Publicado: (2023)

mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
por: Azzolini, Elena, et al.
Publicado: (2022)

Risk factors and outcome of COVID-19 in patients with hematological malignancies
por: Piñana, José Luis, et al.
Publicado: (2020)

Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens
por: Piñana, José Luis, et al.
Publicado: (2020)

CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
por: Velasco, Roser, et al.
Publicado: (2023)

Evaluation of a multiplex panel for the diagnosis of acute infectious diarrhea in immunocompromised hematologic patients
por: Alejo-Cancho, Izaskun, et al.
Publicado: (2017)

The Biological and Hematological Effects of Echinacea purpurea L. Roots Extract in the Immunocompromised Rats with Cyclosporine
por: Khattab, Hala A.H., et al.
Publicado: (2019)

Primary Spinal Infections in Patients With Hematologic Immunocompromising Conditions: A Systematic Literature Review
por: Devico Marciano, Naomie, et al.
Publicado: (2023)

Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation
por: Van Genechten, T., et al.
Publicado: (2020)

2334. The effectiveness of bivalent COVID-19 booster among patients with hematologic malignancies
por: Aleissa, Muneerah M, et al.
Publicado: (2023)

Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents
por: Kim, Yoo-Yeon, et al.
Publicado: (2022)

Life-Threatening VIPoma Crisis in an Immunocompromised Patient
por: Borhan, Marisa Khatijah, et al.
Publicado: (2021)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies
por: Huang, Chien-Tzu, et al.
Publicado: (2023)

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
por: Blixt, Lisa, et al.
Publicado: (2022)

Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021
por: Lin, Kuan-Yin, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 booster vaccines
por: Loving, Hanna S., et al.
Publicado: (2022)

Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022
por: Gálvez, Jubby Marcela, et al.
Publicado: (2023)

Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies
por: Sfeir, Maroun M., et al.
Publicado: (2020)

The Effects of Green Tea Catechins in Hematological Malignancies
por: Della Via, Fernanda Isabel, et al.
Publicado: (2023)

2939. Hepatitis A vaccine immunogenicity in an immunocompromised population: a prospective cohort study
por: Schnyder, Jenny, et al.
Publicado: (2023)

Fatal Disseminated Mucormycosis in a Hematological Immunocompromised Patient with Extensive Voriconazole Exposure: A Case Report and Review of the Literature
por: Humphrey, Victoria S., et al.
Publicado: (2020)

Serum lactate is associated with increased illness severity in immunocompromised pediatric hematology oncology patients presenting to the emergency department with fever
por: Slatnick, Leonora Rose, et al.
Publicado: (2022)

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study
por: Schönlein, Martin, et al.
Publicado: (2022)

Isolated cerebral Mucormycosis and Aspergillosis coinfection in an immunocompromised adult
por: Sun, George, et al.
Publicado: (2023)

Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
por: Krekeler, Carolin, et al.
Publicado: (2022)

Hematological and biochemical findings in patients with dengue fever: a current issue
por: da Cunha, Rivaldo Venâncio, et al.
Publicado: (2012)

Infections in the Immunocompromised
por: Cant, Andrew, et al.
Publicado: (2009)

Immunocompromised Patients
por: Humphreys, Hilary, et al.
Publicado: (2012)

Disseminated Histoplasmosis in Central California Seen in an Immunocompromised Patient
por: Ghadiya, Kishan, et al.
Publicado: (2023)

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study
por: De Ramón, Cristina, et al.
Publicado: (2020)

Hematologic Complications
por: Martin, Ralitza, et al.
Publicado: (2014)

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
por: Rescigno, Maria, et al.
Publicado: (2023)

Manifestations and outcomes of nocardia infections: Comparison of immunocompromised and nonimmunocompromised adult patients
por: Steinbrink, Julie, et al.
Publicado: (2018)

COVID Antibody Production Following Vaccination in Immunocompromised Subjects- A Quality Improvement Project
por: Ghannam, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_02gagv5hf4ind0ts66r8oauk14